WG
EDIT icon

Winton Group’s Editas Medicine EDIT Stock Holding History

Winton Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Sell
43,700
-100
-0.2% -$292 ﹤0.01% 1051
2026
Q1 		$108K Buy
+43,800
New +$92.7K ﹤0.01% 1036
2023
Q2 		– Sell
-20,824
Closed -$151K – 871
2023
Q1 		$151K Sell
20,824
-306
-1% -$2.72K 0.01% 916
2022
Q4 		$187K Buy
21,130
+1,201
+6% +$13.2K 0.01% 873
2022
Q3 		$244K Sell
19,929
-2,473
-11% -$38.5K 0.02% 848
2022
Q2 		$265K Buy
22,402
+4,766
+27% +$63.9K 0.01% 831
2022
Q1 		$335K Buy
17,636
+3,307
+23% +$61.5K 0.02% 790
2021
Q4 		$380K Buy
+14,329
New +$493K 0.02% 757
2021
Q1 		– Sell
-7,723
Closed -$541K – 1389
2020
Q4 		$541K Sell
7,723
-37,661
-83% -$1.55M 0.04% 754
2020
Q3 		$1.27M Buy
45,384
+33,962
+297% +$1.11M 0.04% 708
2020
Q2 		$338K Sell
11,422
-14,163
-55% -$370K 0.01% 1257
2020
Q1 		$507K Buy
+25,585
New +$645K 0.01% 1027

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Winton Group's EDIT Position: Q2 2026 in Review

Winton Group reduced its Editas Medicine (EDIT) stake by 0.23% in Q2 2026, selling an estimated $292 and leaving 43,700 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Winton Group first reported a position in EDIT in Q1 2020 and has held it in 12 quarters since. The position peaked at $1.27M in Q3 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Winton Group held 43,700 shares of Editas Medicine worth $142K as of Q2 2026.
  • Winton Group sold 100 Editas Medicine shares in Q2 2026, an estimated $292.
  • Editas Medicine made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1051 holding.
  • Winton Group first reported a position in Editas Medicine in Q1 2020 and has held it in 12 quarters since.
  • Winton Group's Editas Medicine position peaked at $1.27M in Q3 2020.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.